The business press and Wall Street analysts have already laid out many of the reasons for skepticism about Mylan Laboratories Inc. 's proposal to acquire King Pharmaceuticals Inc. for $3.7 billion in stock [See Deal]. But the proposal and reaction to it raises interesting additional questions about business models in specialty pharma, a concept that has, in many ways, taken over the small-company pharma world.
Mylan, one of the nation's top three generics companies, says it is buying King to boost its efforts in the...
